Skin disease linked to gadolinium

Article

The risk that some patients have for developing a debilitating, life-threatening skin disease linked to the administration of gadolinium calls for close scrutiny of kidney function or even a higher threshold of glomular filtration rate.

The risk that some patients have for developing a debilitating, life-threatening skin disease linked to the administration of gadolinium calls for close scrutiny of kidney function or even a higher threshold of glomular filtration rate.

Nearly 400 cases of nephrogenic systemic fibrosis (NSF) have recently been identified worldwide, and most are related to the administration of gadodiamide (Omniscan, GE Healthcare) in patients with moderate to end-stage kidney disease, according to Dr Henrik Thomsen, a radiologist at Copenhagen University Hospital in Denmark.

Patients with a GFR of < 30 mL/min and those on dialysis are at risk, Thomsen said. There also have been reports of patients with a serum creatinine below 2 mg/dL after gadodiamide administration, suggesting that the threshold could be set higher at < 60 mL/min.

GE Healthcare has posted warnings about gadodiamide on its Web site.

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Nina Kottler, MD, MS
Related Content
© 2025 MJH Life Sciences

All rights reserved.